Development of glucose-responsive ‘smart’ insulin systems
AbstractPurpose of review
The complexity of modern insulin-based therapy for type I and type II diabetes mellitus and the risks associated with excursions in blood–glucose concentration (hyperglycemia and hypoglycemia) have motivated the development of ‘smart insulin’ technologies (glucose-responsive insulin, GRI). Such analogs or delivery systems are entities that provide insulin activity proportional to the glycemic state of the patient without external monitoring by the patient or healthcare provider. The present review describes the relevant historical background to modern GRI technologies and highlights three distinct approaches: coupling of continuous glucose monitoring (CGM) to deliver devices (algorithm-based ‘closed-loop’ systems), glucose-responsive polymer encapsulation of insulin, and molecular modification of insulin itself.Recent findings
Recent advances in GRI research utilizing each of the three approaches are illustrated; these include newly developed algorithms for CGM-based insulin delivery systems, glucose-sensitive modifications of existing clinical analogs, newly developed hypoxia-sensitive polymer matrices, and polymer-encapsulated, stem-cell-derived pancreatic β cells.Summary
Although GRI technologies have yet to be perfected, the recent advances across several scientific disciplines that are described in this review have provided a path towards their clinical implementation.